The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer.

ABSTRACT:

Background

Despite recent advances in treating non-small cell lung cancer (NSCLC) with immune checkpoint inhibitors (ICIs), their role in ALK-positive NSCLC patients is unclear. We investigated the efficacy of ICIs in patients with ALK-positive NSCLC.

Methods

Between 2011 and 2018, a total of 14 ALK-positive NSCLC patients treated with ICIs were evaluated retrospectively. Clinicopathologic features including age, PD-L1 expression, and treatment outcomes were analyzed. RNA expression level and cytolytic activity by ALK positivity were analyzed using The Cancer Genome Atlas (TCGA) and National Cancer Center Research Institute (NCCRI) data sets.

Results

A total of 13 patients (92.9%) received ALK inhibitors. Patients received a median of three (range 2-8) courses of ther

SUBMITTER: Heo JY 

PROVIDER: S-EPMC6825904 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature